{"title":"视网膜疾病的处理","authors":"N. Kumar","doi":"10.13172/2052-0077-2-1-371","DOIUrl":null,"url":null,"abstract":"Introduction Many recent researches have contributed immensely in the management of retinal diseases. In this critical review, we discuss the management of retinal diseases. Conclusion Currently, age-related macular degeneration is managed primarily by anti-vascular growth factor agents. Newer reports on combination therapy may help in managing this visually debilitating condition in a better way. There are many new reports regarding the use of aflibercept and Ozurdex® (Allergan Inc., Irvine, California, USA) in the management of diabetic macular oedema and macular oedema associated with retinal vein occlusions. In the light of recent reports, retinopathy of prematurity may be often managed with bevacizumab. Introduction of ocriplasmin and Argus-II Retinal Prosthesis System (Second Sight Medical Products, Inc., Sylmar, California, USA) may offer ophthalmologists newer ways to treat some important vitreoretinal conditions.","PeriodicalId":19393,"journal":{"name":"OA Case Reports","volume":"64 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Management of retinal diseases\",\"authors\":\"N. Kumar\",\"doi\":\"10.13172/2052-0077-2-1-371\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction Many recent researches have contributed immensely in the management of retinal diseases. In this critical review, we discuss the management of retinal diseases. Conclusion Currently, age-related macular degeneration is managed primarily by anti-vascular growth factor agents. Newer reports on combination therapy may help in managing this visually debilitating condition in a better way. There are many new reports regarding the use of aflibercept and Ozurdex® (Allergan Inc., Irvine, California, USA) in the management of diabetic macular oedema and macular oedema associated with retinal vein occlusions. In the light of recent reports, retinopathy of prematurity may be often managed with bevacizumab. Introduction of ocriplasmin and Argus-II Retinal Prosthesis System (Second Sight Medical Products, Inc., Sylmar, California, USA) may offer ophthalmologists newer ways to treat some important vitreoretinal conditions.\",\"PeriodicalId\":19393,\"journal\":{\"name\":\"OA Case Reports\",\"volume\":\"64 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"OA Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.13172/2052-0077-2-1-371\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"OA Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.13172/2052-0077-2-1-371","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Introduction Many recent researches have contributed immensely in the management of retinal diseases. In this critical review, we discuss the management of retinal diseases. Conclusion Currently, age-related macular degeneration is managed primarily by anti-vascular growth factor agents. Newer reports on combination therapy may help in managing this visually debilitating condition in a better way. There are many new reports regarding the use of aflibercept and Ozurdex® (Allergan Inc., Irvine, California, USA) in the management of diabetic macular oedema and macular oedema associated with retinal vein occlusions. In the light of recent reports, retinopathy of prematurity may be often managed with bevacizumab. Introduction of ocriplasmin and Argus-II Retinal Prosthesis System (Second Sight Medical Products, Inc., Sylmar, California, USA) may offer ophthalmologists newer ways to treat some important vitreoretinal conditions.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
